| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/27/2013 | WO2013192594A2 Antigen binding proteins that bind c-met |
| 12/27/2013 | WO2013192589A1 Antibodies targeting hiv escape mutants |
| 12/27/2013 | WO2013192532A2 Peptide conjugated particles |
| 12/27/2013 | WO2013192504A1 Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
| 12/27/2013 | WO2013192319A1 Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| 12/27/2013 | WO2013192240A2 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| 12/27/2013 | WO2013191591A1 Chimeric protein vaccine against pneumonia caused by streptococcus pneumoniae |
| 12/27/2013 | WO2013191445A1 Pharmaceutical composition for colon cancer treatment or metastasis suppression, comprising cadherin-11 protein expression or action suppressing agent |
| 12/27/2013 | WO2013191363A1 Novel bacteriophage, and use for inhibiting proliferation of pathogenic bacteria |
| 12/27/2013 | WO2013191225A1 Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection |
| 12/27/2013 | WO2013191166A1 IgE PEPTIDE VACCINE |
| 12/27/2013 | WO2013190555A1 Lsr antibodies, and uses thereof for treatment of cancer |
| 12/27/2013 | WO2013189901A1 Stabilized gp120 |
| 12/27/2013 | WO2013189554A1 Method for treating a gd2 positive cancer |
| 12/27/2013 | WO2013189516A1 Method for treating a gd2 positive cancer |
| 12/27/2013 | WO2013188936A1 Leptospirosis laboratory diagnostic medium and vaccine against animal leptospirosis |
| 12/27/2013 | WO2013188918A1 Improved recombinant viruses |
| 12/27/2013 | WO2013173364A3 Lingo-2 antagonists for treatment of conditions involving motor neurons |
| 12/27/2013 | WO2013155142A3 Method of modifying spermatogenesis, spermiogenesis and/or fertility in mammals |
| 12/27/2013 | WO2013108126A3 Methyltransferases and uses thereof |
| 12/27/2013 | CA2877814A1 Antigen binding proteins that bind ccr2 |
| 12/27/2013 | CA2877573A1 Antigen binding proteins that bind c-met |
| 12/27/2013 | CA2877533A1 Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
| 12/27/2013 | CA2877299A1 Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| 12/27/2013 | CA2876904A1 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| 12/27/2013 | CA2876762A1 Stabilized gp120 |
| 12/27/2013 | CA2876529A1 Method for treating a gd2 positive cancer |
| 12/27/2013 | CA2876495A1 Peptide conjugated particles |
| 12/27/2013 | CA2875567A1 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| 12/27/2013 | CA2875543A1 Antigen binding proteins that bind igf1r |
| 12/27/2013 | CA2848291A1 Lsr antibodies, and uses thereof for treatment of cancer |
| 12/26/2013 | US20130345409 Growth factor |
| 12/26/2013 | US20130345274 Allantoin-containing skin cream |
| 12/26/2013 | US20130345114 Agent for Treating Allergic or Hypersensitivity Condition |
| 12/26/2013 | US20130344129 Inflammation-regulating compositions and methods |
| 12/26/2013 | US20130344111 Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment with Immune Response Generating Therapies |
| 12/26/2013 | US20130344110 Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast-Based Vaccines |
| 12/26/2013 | US20130344109 Immunogenic Compositions |
| 12/26/2013 | US20130344106 Methods and Compositions for Improving Immune Response by a Nutraceutical Antioxidant |
| 12/26/2013 | US20130344105 Method for augmenting the immunogenicity of an antigen |
| 12/26/2013 | US20130344104 Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine |
| 12/26/2013 | US20130344100 Virus like particle production in plants |
| 12/26/2013 | US20130344097 Ras Mutation and Compositions and Methods Related Thereto |
| 12/26/2013 | US20130344093 Anti-EGFR Antibodies and Uses Thereof |
| 12/26/2013 | US20130344092 Methods of Using Anti-Thymocyte Globulin and Related Agents |
| 12/26/2013 | US20130344091 Compositions and methods for increasing muscle growth |
| 12/26/2013 | US20130344088 Antibody formulation |
| 12/26/2013 | US20130344082 Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| 12/26/2013 | US20130344081 Method of treating amyotrophic lateral sclerosis |
| 12/26/2013 | US20130344080 PILR alpha Interactions and Methods of Modifying Same |
| 12/26/2013 | US20130344079 Compositions and methods for diagnosing and treating phenylketonuria (pku) |
| 12/26/2013 | US20130344077 Monoclonal antibodies |
| 12/26/2013 | US20130344073 Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders |
| 12/26/2013 | US20130344068 Methods of preventing inflammation and treating pain using anti-ngf compositions |
| 12/26/2013 | US20130344067 Alk1 receptor and ligand antagonists and uses thereof |
| 12/26/2013 | US20130344065 Combination Treatment with VEGF-C Antagonists |
| 12/26/2013 | US20130344064 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
| 12/26/2013 | US20130344060 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 12/26/2013 | US20130344059 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 12/26/2013 | US20130344030 Macrocyclic inhibitors of flaviviridae viruses |
| 12/26/2013 | US20130344029 Macrocyclic inhibitors of flaviviridae viruses |
| 12/26/2013 | US20130343996 Graphite-coated magnetic nanoparticles |
| 12/26/2013 | US20130343988 Pyrido [2, 3-D] pyrimidin-7-one compounds as inhibitors of P13K-Alpha for the treament of cancer |
| 12/25/2013 | EP2676967A2 Methods of treating inflammatory and autoimmune diseases with natalizumab |
| 12/25/2013 | EP2676679A2 Formulations which stabilize and inhibit precipitation of immunogenic compositions |
| 12/25/2013 | EP2676677A1 Highly concentrated anti-cd40 antibody pharmaceutical preparation |
| 12/25/2013 | EP2676676A1 Recombinant viral vectors |
| 12/25/2013 | EP2675478A2 Compositions and methods for the therapy and diagnosis of influenza |
| 12/25/2013 | EP2675477A2 Treatment of fistulizing crohn's disease |
| 12/25/2013 | EP2675476A1 Commercial scale process for production of prrsv |
| 12/25/2013 | EP2675475A2 Novel european prrsv strain |
| 12/25/2013 | EP2675474A1 Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
| 12/25/2013 | EP2675473A1 Methods for enhancing immunogen specific immune responses by vectored vaccines |
| 12/25/2013 | EP2675467A1 Use of mdl-1 antagonists to treat spondylarthropathy |
| 12/25/2013 | EP2569267B1 Improved methods for preparing squalene |
| 12/25/2013 | EP2522719B1 Influenza hemagglutinin and neuraminidase variants |
| 12/25/2013 | EP2223997B1 Method for producing multiple modifications in the chromosome of gram-negative bacteria and salmonella strains which are deficient in c-di-gmp synthesis obtained by said method |
| 12/25/2013 | EP2195026B1 Anti-sclerostin antibodies |
| 12/25/2013 | EP2099483B1 Immunization protocol against the 4 dengue serotypes |
| 12/25/2013 | EP2016952B1 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| 12/25/2013 | EP1999148B1 Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 12/25/2013 | EP1998799B1 Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 12/25/2013 | CN1968710B Stable peptide mimetic of HIV gp41 fusion intermediate |
| 12/25/2013 | CN1856323B Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in treatment of cancers |
| 12/25/2013 | CN1688606B Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| 12/25/2013 | CN103476929A Influenza virus neutralizing antibody and method for screening same |
| 12/25/2013 | CN103476799A Fusion proteins and combination vaccines comprising haemophilus influenzae protein E and pilin A |
| 12/25/2013 | CN103476797A Pharmaceutical compositions comprising human antibodies to PCSK9 |
| 12/25/2013 | CN103476793A Subcutaneously administered anti-IL-6 receptor antibody |
| 12/25/2013 | CN103476786A Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method |
| 12/25/2013 | CN103476430A Dosing for treatment with anti-EGFl7 antibodies |
| 12/25/2013 | CN103476429A Novel modulators and methods of use |
| 12/25/2013 | CN103476427A Conjugates utilizing platform technology for stimulating immune response |
| 12/25/2013 | CN103476426A Yeast-based therapeutic for chronic hepatitis b infection |
| 12/25/2013 | CN103476425A Attenuated viruses useful for vaccines |
| 12/25/2013 | CN103476424A CYAA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
| 12/25/2013 | CN103476407A Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1 |
| 12/25/2013 | CN103468743A Novel rabies vaccine and preparation method thereof |
| 12/25/2013 | CN103468650A Application of human embryonic lung fibroblast strains in preparation of rabies inactivated vaccine |
| 12/25/2013 | CN103468647A Swine flu H1N1 and H3N2 subtype bivalent inactivated vaccine |